Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03690739
Recruitment Status : Recruiting
First Posted : October 1, 2018
Last Update Posted : February 21, 2020
Sponsor:
Information provided by (Responsible Party):
AGO Research GmbH

Brief Summary:
This is an open-label, prospective, randomized, controlled, parallel group, multi-center phase III trial to evaluate the Symptom Benefit Rate of trabectedin/PLD in patients with recurrent ovarian cancer who achieve a stabilization of disease after 3 cycles of platinum-based reinduction therapy and with no clinical benefit.

Condition or disease Intervention/treatment Phase
Recurrent Ovarian Carcinoma Drug: Carboplatin Drug: Gemcitabine Drug: Bevacizumab Drug: PLD Drug: Paclitaxel Drug: Trabectedin Drug: Cisplatin Phase 3

Detailed Description:

Approximately 330 patients will be randomized in a 1:1 ration to the treatments specified below:

Arm A - Platinum-based chemotherapy according to investigator's discretion Arm B - Pegylated liposomal doxorubicin 30 mg/m² + Trabectedin 1.1 mg/m² (q3w)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 330 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Trabectedin/PLD Versus Continuation of Platinum-based Chemo-therapy in Patients With Disease Stabilization and no Symptom Benefit Under Platinum-based Chemotherapy for Recurrent Ovarian Cancer
Actual Study Start Date : August 9, 2019
Estimated Primary Completion Date : August 1, 2023
Estimated Study Completion Date : December 31, 2023


Arm Intervention/treatment
Active Comparator: platinum-based chemotherapy
According to the investigator's discretion
Drug: Carboplatin
Administration according to investigator's discretion

Drug: Gemcitabine
Administration according to investigator's discretion

Drug: Bevacizumab
Administration according to investigator's discretion

Drug: PLD
Administration according to investigator's discretion

Drug: Paclitaxel
Administration according to investigator's discretion

Drug: Cisplatin
Administration according to investigator's discretion

Active Comparator: PLD + Trabectedin
PLD 30 mg/m² + Trabectedin 1.1 mg/m² q21
Drug: PLD
Administration 30 mg/m² q21

Drug: Trabectedin
Administration 1.1 mg/m² q21




Primary Outcome Measures :
  1. Symptom Benefit Rate [ Time Frame: from Baseline to 8 or 9 weeks after randomization, assessed at each visit ]
    Proportion of patients achieving a symptom benefit defined as an at least 10-point improvement according to EORTC QLQ-OV28; EORTC QLQ-OV28 is a questionnaire regarding Quality of Life specialized for Ovarian Cancer with points from 1 till 4 for each of the 28 questions (1=not at all, 2=a little, 3=quite a bit, 4=very much). Points will be summarized.


Secondary Outcome Measures :
  1. Time until definitive deterioration (TUDD ) [ Time Frame: from Baseline until 24 months after randomization, assessed up to 54 months at each visit ]
    TUDD is defined as time from baseline until the first decrease in EORTC QLQ-C30 score ≥ 10 points (or 20 points) as compared at baseline; EORTC QLQ-C30 is a questionnaire regarding Quality of Life specialized for Cancer with points for each of the 30 questions (1=not at all, 2=a little, 3=quite a bit, 4=very much). Points will be summarized.

  2. Progression-free survival (PFS) [ Time Frame: PFS is defined as time from randomization to disease progression according to RECIST v1.1, to death from any cause or to start of a new treatment (whichever occurs first), assessed up to 54 months ]
    Progressive disease is based on investigator assessment using RECIST v1.1

  3. Progression-free survival (PFS) rate at 6 months [ Time Frame: PFS is defined as time from randomization to disease progression according to RECIST v1.1, to death from any cause or to start of a new treatment (whichever occurs first) after six months ]
    Progressive disease is based on investigator assessment using RECIST v1.1

  4. Response Rate (RR) [ Time Frame: from randomization until patients achieving complete response (CR) or partial response (PR) as best overall response, assessed up to 54 months ]
    RR is based on investigator assessment using RECIST v1.1

  5. Global Health Status [ Time Frame: from baseline to end of treatment, assessed up to 54 months at each visit ]
    based on Quality of Life; EORTC QLQ-C30 and EORTC QLQ-OV 28 are questionnaires for Quality of Life with points for each of the 30 or 28 questions (1=not at all, 2=a little, 3=quite a bit, 4=very much). Points will be summarized.

  6. Overall Survival (OS) [ Time Frame: OS is defined as the time from randomization to death from any cause, assessed up to 54 months ]
    regular patient contact during the trila regarding life status



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Females aged ≥ 18 years at time of signing informed consent form.
  2. Histologically proven diagnosis of cancer of the ovary, the fallopian tube or primary peritoneal cancer.
  3. Measurable or non-measurable disease (according RECIST v1.1) or CA-125 assessable disease (according GCIG criteria) or histologically proven diagnosis of relapse.
  4. Platinum-treatment free interval (TFIp) > 6 months prior to cycle 1 day 1 of reinduction therapy.
  5. Disease stabilization without remission or progression ac-cording to RECIST or GCIG criteria after three cycles of platinum-based chemotherapy for recurrent disease.
  6. Symptomatic disease at time of baseline abdominal/GI symptom scale score >15 (EORTC QLQ-OV28)
  7. Completion of EORTC QLQ-OV28 at Baseline within 7 days prior to treatment start.
  8. Patients should have received previously a taxane derivative.
  9. ECOG performance status ≤ 2.
  10. Life expectancy of at least 12 weeks.
  11. Adequate bone marrow, renal and hepatic function defined as:

    • Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
    • Platelet count ≥ 100 x 10^9/L
    • Hemoglobin ≥ 9.0 g/dL
    • Serum creatinine ≤1.5 mg/dL (≤ 132.6 µmol/L) or creatinine clearance ≥ 60 mL/min
    • Creatine phosphokinase (CPK) ≤ 2.5 x ULN
    • Serum aspartate aminotransferase (AST, SGOT) or alanine aminotransferase (ALT, SGPT) ≤ 2.5 x ULN (≤ 5 x ULN in the presence of liver metastases)
    • Alkaline phosphatase (ALP) ≤ 2.5 ULN
    • Serum bilirubin ≤ ULN
    • Albumin ≥ 25 g/l
  12. Participation in an informed consent discussion with the appropriate trial-related health care representative, full understanding of the implications and constraints of the protocol, and provision of written informed consent prior to the commencement of the trial-related procedures.
  13. Geographically accessibility for treatment and follow-up.
  14. For women of childbearing potential (WOCBP): agreement to remain abstinent (refrain from heterosexual inter-course) or use a contraceptive method with a failure rate of < 1 per-centage per year during the treatment period and for at least six months after administration of the last dose of chemo-therapy. A woman is considered to be of childbearing po-tential if she is postmenarcheal, has not reached a post-menopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries, fal-lopian tubes, and/or uterus). Examples of contraceptive methods with a failure rate of < 1 percentage per year in-clude but are not limited to bilateral tubal ligation and/or oc-clusion, male sterilization, and intrauterine devices, and nor-mal and low dose combined oral pill plus male condom or Cerazette (desogestrel) plus male condom. Cerazette is currently the only highly efficacious progesterone based pill. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation meth-ods) and withdrawal are not acceptable methods of contra-ception.

Exclusion Criteria:

  1. Ovarian tumors of low malignant potential (e.g. borderline tumors).
  2. Non-epithelial ovarian or mixed epithelial/non epithelial tumors (e.g. mixed Müllerian tumors).
  3. Patients with an objective response in terms of a partial or complete remission or alternatively progressive disease ac-cording to RECIST or GCIG criteria after three cycles of platinum-based reinduction chemotherapy.
  4. Patients who have received previous radiotherapy for ovarian cancer.
  5. History of congestive heart failure (NYHA classification > 2, even if medically con-trolled).
  6. History of myocardial infarction within the last six months (documented or by electrocardiogram).
  7. History of atrial or ventricular arrhythmias.
  8. Impaired liver function, hyperbilirubinemia, Serum creatinine >1.5 mg/dL or > 132.6 μmol/L or creatinine clearance < 60 mL/min, left ventricular ejection fraction < 45 %.
  9. Severe active or uncontrolled infection.
  10. Concurrent severe medical problems unrelated to malignancy, which would significantly limit full compliance with the trial or expose the patient to extreme risk or decreased life expectancy.
  11. Patients with known hypersensitivity to the active substance or their compounds related to trabectedin or PLD and patients with known hypersensitivity to one of active substances or one of their compounds used in platinum-based chemotherapy as described in the Summaries of Medicinal Products.
  12. Patients with potential risks according to contraindication, warnings or interactions of the used chemotherapeutic agents as stated in the SmPCs are not eligible for participation in this trial.
  13. Patients with contraindication regarding CT or MRI (only in case of contrast allergy) are excluded.
  14. Women of childbearing potential (WOCBP) not using highly effective contraceptive methods.
  15. Pregnancy or breast-feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03690739


Contacts
Layout table for location contacts
Contact: Michaela Fredrich +49 611 880 4670 mfredrich@ago-ovar.de

Locations
Show Show 29 study locations
Sponsors and Collaborators
AGO Research GmbH
Investigators
Layout table for investigator information
Study Chair: Felix Hilpert, MD, PhD Mammazentrum am Krankenhaus Jerusalem, Hamburg
Layout table for additonal information
Responsible Party: AGO Research GmbH
ClinicalTrials.gov Identifier: NCT03690739    
Other Study ID Numbers: AGO-OVAR 2.32
First Posted: October 1, 2018    Key Record Dates
Last Update Posted: February 21, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AGO Research GmbH:
Symptom Benefit
Additional relevant MeSH terms:
Layout table for MeSH terms
Gemcitabine
Paclitaxel
Bevacizumab
Carboplatin
Trabectedin
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Antineoplastic Agents, Alkylating
Alkylating Agents